Array BioPharma announced positive results from the Phase III BEACON CRC trial evaluating a triple combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovia (binimetinib), and the anti-EGFR antibody Erbitux (cetuximab) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer after one or two lines of therapy.
Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group.
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient […]
Roche buoyed by early data on atezolizumab in advanced melanoma
Advanced Melanoma, Bladder Cancer, BRAF Inhibitors, BRAF V600 Inhibitors, Health, Hemophilia, Hemophilia, Immune System, Immune Systems, Lung Cancer, Melanoma, Multiple Sclerosis, Multiple Sclerosis, Potential Blockbusters, R&D, Studies, Targeted Therapies, TherapeuticsSwiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma. A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]
Array BioPharma And Pierre Fabre Announce Development And Commercialization Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib
Asia, Biopharma, BRAF Inhibitors, Canada, Clinical Trials, Collaboration, Collaborations, Europe, Health, Israel, Japan, Korea, Latin America, MEK Inhibitors, Melanoma, Ovarian Cancer, R&D, Royalties– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]